Quantcast

Industry news that matters to you.  Learn more

Assurex Health Releases Enhanced Pharmacogenomic Test to Help Clinicians Select Medications for Depression, Anxiety and PTSD

Assurex Health recently announced an enhancement of its GeneSight® Psychotropic test, providing clinicians with the most comprehensive genetic-based tool available to help them make individualized antidepressant and antipsychotic medication decisions for patients with depression, anxiety, post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia and other behavioral health disorders. GeneSight Psychotropic now covers 38 FDA-approved medications, including recently approved levomilnacipran (Fetzima®) and vortioxetine (Brintellix®).

Assurex Health Launches Comprehensive Genetic-Based Test to Help Clinicians Select Pain Medications for Patients

Assurex Health, Inc. recently announced a significant expansion of its GeneSight® Analgesic test.  The expanded test gives clinicians a multi-gene pharmacogenomics tool to guide medication decisions for patients with acute or chronic pain using patients’ own genetic profiles to help determine their potential response to 22 medications across four relevant medication classes: opioids, NSAIDs, muscle relaxants, and opioid dependency.

Cincinnati Children’s Issued Patent Covering Individualized Medication Dosing Technology Being Commercialized by Assurex Health

Cincinnati Children’s Hospital Medical Center (CCHMC) and Assurex Health recently announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,589,175 encompassing the “Optimization and Individualization of Medication Selection and Dosing” by Cincinnati Children’s inventors Drs. Tracy A. Glauser, Richard J. Wenstrup*, Alexander A. Vinks, and John P. Pestian. The CCHMC patent covers methods for optimizing dosing regimens for medications utilizing population models, genotype, and clinical information to treat patients with neuropsychiatric and other disorders.

CAMH and Assurex Health Launch Joint Venture to Advance Personalized Medicine in Canada

The Centre for Addiction and Mental Health (CAMH), Canada’s leading hospital for mental health, and Assurex Health, a global leader in personalized medicine, have signed an agreement for a joint venture to bring the benefits of this treatment approach to more Canadians.

Third Clinical Study Confirms Treatment Guided By GeneSight Psychiatric Pharmacogenomics Test

Assurex Health, a leading personalized medicine company, recently announced the publication of a third clinical study providing evidence for the effectiveness of the GeneSight combinatorial pharmacogenomic test over the current method for selecting psychotropic medications. The study results were published in the November 2013 issue of Discovery Medicine. Consistent with two previous clinical trials, the Pine Rest study concluded that patients are more than twice as likely to respond when treatment is guided by GeneSight compared to treatment as usual. Importantly, GeneSight also identified 30% of patients with severe gene-drug interactions who had the greatest improvement in depressive symptoms when switched to medications concordant with their genetic profile.